Global radiopharmaceutical leader Curium™ has acquired Abscint SA, a Belgian clinical-stage company developing innovative diagnostic imaging agents for oncology.
The deal marks a significant milestone for the Belgian life sciences company, arriving precisely as it prepares to scale its operations for the next phase of clinical development.
“Curium’s scale, expertise and long-standing focus on nuclear medicine make it well positioned to support the next phase of development for this important programme,” explains Abscint SA CEO Karine Clauwaert (pictured).
The sale also sees Curium gain the global rights to develop, manufacture and commercialise ABS-011, an investigational gallium-68-labelled positron emission tomography (PET) radiodiagnostic tracer designed to target human epidermal growth factor receptor 2 (HER2). “We believe ABS-011 could help provide a more complete picture of HER2 expression across the body, with the potential to guide optimal care for patients with cancers where HER2 plays an important role,” reveals Curium Biopharma CEO Chait Tatineni.
The integration of Abscint’s technology bolsters Curium’s robust oncology pipeline. The company plans to leverage its extensive experience in radiopharmaceutical manufacturing and commercialisation to guide ABS-011 through regulatory review and ultimately to market. “Alongside the Abscint team, Curium strengthens capabilities to help advance this program toward regulatory approval and ultimately access by patients who may benefit from it,” Chait elaborates.
ABS-011 is currently being evaluated in the HERMIA trial, a multicentered Phase 2b clinical trial in Belgium (NCT 06369831).
“Abscint has worked to develop a differentiated approach to HER2 imaging, driven by the belief that better diagnostics can lead to better care,” Karine adds. “We are pleased that Curium will help advance ABS-011 into its next stage of development.”
She sees this as a deeply personal milestone. “I’m incredibly proud of our team and grateful to everyone who believed in us along the way. One chapter closes; a much bigger one begins,” Karine concludes.
